Ken Griffin Enveric Biosciences, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$12.5 - $52.0 $1.21 Million - $5.03 Million	-96,805 Reduced 62.4%	58,332 $20,000
Q4 2021 Feb 14, 2022	BUY	$46.5 - $104.0 $3.18 Million - $7.12 Million	68,488 Added 79.04%	155,137 $7.21 Million
Q3 2021 Nov 15, 2021	BUY	$80.5 - $175.0 $5.92 Million - $12.9 Million	73,564 Added 562.2%	86,649 $179,000
Q2 2021 Aug 16, 2021	BUY	$95.0 - $156.5 $1.24 Million - $2.05 Million	13,085 New	13,085 $1.56 Million
Q1 2021 May 17, 2021	SELL	$131.5 - $245.0 $1.34 Million - $2.5 Million	-10,199 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$74.0 - $740.0 $754,726 - $7.55 Million	10,199 New	10,199 $43,000

Ticker ENVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,078,270
Market Cap $665K
Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.